Finally, while it can be argued that the treatment of ovarian cancer patients with HO-3867—preferably as an adjuvant to conventional therapies—could improve outcomes for these patients, its effect is only possible for those cancers that harbor a TP53 missense mutation. This evidence concerns the gene TP53 and cancer.